Chugai Pharmaceutical (OTCMKTS:CHGCY) Sets New 1-Year High – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) shares reached a new 52-week high during mid-day trading on Friday . The company traded as high as $26.24 and last traded at $25.49, with a volume of 68174 shares changing hands. The stock had previously closed at $24.42.

Chugai Pharmaceutical Stock Performance

The stock has a 50-day simple moving average of $21.98 and a 200 day simple moving average of $22.74. The company has a market cap of $83.89 billion, a P/E ratio of 33.10 and a beta of 0.81.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.18 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. Sell-side analysts anticipate that Chugai Pharmaceutical Co., Ltd. will post 0.74 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.